---
title: "Maintenance Intensification After Autologous HSCT: Refining Selection"
id: "the-lancet-haematology-2-maintenance-intensification-after-autologous-hsct-refining-selection"
canonical_url: "https://medichelpline.com/clinical-feed/the-lancet-haematology-2-maintenance-intensification-after-autologous-hsct-refining-selection"
content_type: "clinical_feed_article"
specialty: "Hematology"
source_name: "The Lancet Haematology"
source_url: "https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00064-5/fulltext?rss=yes"
doi: "10.1016/S2352-3026(26)00064-5"
published_at: "2026-03-11T23:30:01.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Maintenance Intensification After Autologous HSCT: Refining Selection
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/the-lancet-haematology-2-maintenance-intensification-after-autologous-hsct-refining-selection
- **Specialty:** [Hematology](https://medichelpline.com/clinical-feed/hematology.md)
- **Primary Source:** The Lancet Haematology
- **Source URL:** [Original Journal Publication](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00064-5/fulltext?rss=yes)
- **DOI:** [10.1016/S2352-3026(26)00064-5](https://doi.org/10.1016%2FS2352-3026(26)00064-5)
- **Published At:** 2026-03-11T23:30:01.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
In The Lancet Haematology, Dominik Dytfeld and colleagues1 report the findings from the phase 3 ATLAS trial, comparing carfilzomib–lenalidomide–dexamethasone with lenalidomide alone as maintenance therapy after autologous haematopoietic stem-cell transplantation (HSCT) in patients with newly diagnosed multiple myeloma. Lenalidomide monotherapy has long been the global standard of care in this setting, based on consistent improvements in progression-free survival and overall survival.2 With a median follow-up of nearly 6 years, carfilzomib–lenalidomide–dexamethasone maintenance significantly improved 4-year progression-free survival (67·5% [95% CI 56·2–76·4] vs 38·0% [27·6–48·2]; hazard ratio 0·46 [95% CI 0·30–0·70]) with a manageable safety profile.
## Clinical Analysis & Structured Key Points
The Lancet Haematology published a clinical update in Oncology on 11 Mar 2026. The item focuses on Maintenance intensification after autologous HSCT: refining selection. Review the original article for the full source wording and details.
## Related Clinical Research

- [Daratumumab‑VCD for Newly Diagnosed AL Amyloidosis: ANDROMEDA Final Survival Analysis (Blood 2026)](https://medichelpline.com/clinical-feed/pubmed-42118698.md) (DOI: 10.1182/blood.2025032099)
- [Correction to Lancet Haematol 2026; 13: e241–53](https://medichelpline.com/clinical-feed/the-lancet-haematology-7-correction-to-lancet-haematol-2026-13-e241-53.md) (DOI: 10.1016/S2352-3026(26)00077-3)
- [Carfilzomib, Lenalidomide, and Dexamethasone After Autologous Stem-Cell Transplantation in Multi](https://medichelpline.com/clinical-feed/the-lancet-haematology-14-carfilzomib-lenalidomide-and-dexamethasone-compared-with-lenalidomide-treatment-after-autologous-haematopoietic-stem-cell-transplantation-in-patients-with-multiple-myeloma-atlas-primary-analysis-of-a-randomised-open-label-phase-3-trial.md) (DOI: 10.1016/S2352-3026(26)00011-6)
- [Intravenous dexamethasone prolongs analgesia after supraclavicular brachial plexus block: randomiz](https://medichelpline.com/clinical-feed/pubmed-42691058.md) (DOI: 10.1371/journal.pone.0338067)
- [OCTA quantifies choroidal and retinal thinning and blood flow loss in lens-induced myopia rats](https://medichelpline.com/clinical-feed/plos-one-17-quantitative-analysis-of-choroidal-and-retinal-thickness-and-blood-flow-in-a.md)

## Navigation
- [← Back to Hematology Feed](https://medichelpline.com/clinical-feed/hematology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.